TY - JOUR
T1 - The outcome of chemotherapy for metastatic extramammary paget’s disease
AU - Hashimoto, Hiroki
AU - Kaku-Ito, Yumiko
AU - Furue, Masutaka
AU - Ito, Takamichi
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/2/2
Y1 - 2021/2/2
N2 - The efficacy and survival impact of conventional chemotherapies for metastatic extra-mammary Paget’s disease (EMPD) have not been fully elucidated. This study examined the long-term outcome of chemotherapy for this indication. We conducted a retrospective review of 21 patients with distant metastatic EMPD (14 patients treated with chemotherapy and 7 patients treated without chemotherapy). The response rate of chemotherapy and patient survival were statistically analyzed. Among the 14 patients treated with chemotherapy, 12, 1, and 1 patient received docetaxel, paclitaxel, and low-dose 5-fluorouracil plus cisplatin, respectively, as the first-line treatment. The response rate was 50.0% (7/14), and the disease control rate was 64.3% (9/14). The median progres-sion-free survival (PFS) and overall survival (OS) were 16.8 and 27.9 months, respectively. Multi-variate analyses revealed that chemotherapy was a significant factor for prolonged PFS (hazard ratio (HR) 0.22, p = 0.038) but not for OS (HR = 1.71, p = 0.54). Ten patients (71.4%) had severe (grade 3 or 4) hematological adverse events. Although conventional chemotherapy improved PFS, we failed to show a significantly improved OS. Considering the frequent adverse events of conventional chem-otherapy, targeted therapy may become a mainstay for the treatment of metastatic EMPD.
AB - The efficacy and survival impact of conventional chemotherapies for metastatic extra-mammary Paget’s disease (EMPD) have not been fully elucidated. This study examined the long-term outcome of chemotherapy for this indication. We conducted a retrospective review of 21 patients with distant metastatic EMPD (14 patients treated with chemotherapy and 7 patients treated without chemotherapy). The response rate of chemotherapy and patient survival were statistically analyzed. Among the 14 patients treated with chemotherapy, 12, 1, and 1 patient received docetaxel, paclitaxel, and low-dose 5-fluorouracil plus cisplatin, respectively, as the first-line treatment. The response rate was 50.0% (7/14), and the disease control rate was 64.3% (9/14). The median progres-sion-free survival (PFS) and overall survival (OS) were 16.8 and 27.9 months, respectively. Multi-variate analyses revealed that chemotherapy was a significant factor for prolonged PFS (hazard ratio (HR) 0.22, p = 0.038) but not for OS (HR = 1.71, p = 0.54). Ten patients (71.4%) had severe (grade 3 or 4) hematological adverse events. Although conventional chemotherapy improved PFS, we failed to show a significantly improved OS. Considering the frequent adverse events of conventional chem-otherapy, targeted therapy may become a mainstay for the treatment of metastatic EMPD.
UR - http://www.scopus.com/inward/record.url?scp=85110505086&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110505086&partnerID=8YFLogxK
U2 - 10.3390/jcm10040739
DO - 10.3390/jcm10040739
M3 - Article
AN - SCOPUS:85110505086
VL - 10
SP - 1
EP - 15
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
SN - 2077-0383
IS - 4
M1 - 739
ER -